Prince Pharmaceutical Co., Ltd. (TPEX:6935)
Taiwan · Delayed Price · Currency is TWD 29.65
0.00 (0.00%)
Jul 30, 2026, 9:59 AM CST
Prince Pharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,056 | 690.03 | 753.33 | 712.53 | 441.08 | |
Revenue Growth | 53.07% | -8.40% | 5.73% | 61.54% | 49.12% |
Cost of Revenue | 833.65 | 615.75 | 600.23 | 506.74 | 315.59 |
Gross Profit | 222.55 | 74.28 | 153.09 | 205.79 | 125.49 |
Selling, General & Admin | 77.04 | 75.43 | 72.74 | 65.9 | 47.38 |
Research & Development | 34.64 | 48.2 | 54.67 | 72.05 | 79.21 |
Operating Expenses | 111.68 | 123.63 | 127.31 | 138.03 | 126.6 |
Operating Income | 110.87 | -49.35 | 25.78 | 67.76 | -1.11 |
Interest Expense | -9.58 | -10.27 | -10.46 | -8.94 | -7.55 |
Interest & Investment Income | 0.9 | 1.3 | 1.16 | 0.22 | 0.03 |
Currency Exchange Gain (Loss) | - | - | - | 4.18 | -1 |
Other Non Operating Income (Expenses) | 2.72 | 6.38 | 2.63 | 0.92 | -0.76 |
EBT Excluding Unusual Items | 104.91 | -51.95 | 19.11 | 64.14 | -10.4 |
Gain (Loss) on Sale of Assets | -0.17 | -0.14 | 0.06 | 0.06 | 0.09 |
Pretax Income | 104.74 | -52.08 | 19.17 | 64.2 | -10.31 |
Income Tax Expense | 8.42 | 1.46 | 3.86 | 12.65 | -2.01 |
Net Income | 96.32 | -53.54 | 15.31 | 51.55 | -8.3 |
Net Income to Common | 96.32 | -53.54 | 15.31 | 51.55 | -8.3 |
Net Income Growth | - | - | -70.30% | - | - |
Shares Outstanding (Basic) | 37 | 37 | 36 | 33 | 33 |
Shares Outstanding (Diluted) | 37 | 37 | 37 | 33 | 33 |
Shares Change | 1.03% | 0.09% | 9.66% | 0.41% | 1.45% |
EPS (Basic) | 2.62 | -1.46 | 0.43 | 1.55 | -0.25 |
EPS (Diluted) | 2.61 | -1.46 | 0.42 | 1.55 | -0.25 |
EPS Growth | - | - | -72.90% | - | - |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 71.81 | 28.21 | 0.45 | 72.13 | 1.38 |
Free Cash Flow Per Share | 1.94 | 0.77 | 0.01 | 2.16 | 0.04 |
Dividend Per Share | 0.500 | - | 0.250 | 0.150 | - |
Dividend Growth | - | - | 66.67% | - | - |
Gross Margin | 21.07% | 10.76% | 20.32% | 28.88% | 28.45% |
Operating Margin | 10.50% | -7.15% | 3.42% | 9.51% | -0.25% |
Profit Margin | 9.12% | -7.76% | 2.03% | 7.23% | -1.88% |
Free Cash Flow Margin | 6.80% | 4.09% | 0.06% | 10.12% | 0.31% |
EBITDA | 163.6 | 4.54 | 75.94 | 113.7 | 40.05 |
EBITDA Margin | 15.49% | 0.66% | 10.08% | 15.96% | 9.08% |
D&A For EBITDA | 52.74 | 53.89 | 50.16 | 45.93 | 41.16 |
EBIT | 110.87 | -49.35 | 25.78 | 67.76 | -1.11 |
EBIT Margin | 10.50% | -7.15% | 3.42% | 9.51% | -0.25% |
Effective Tax Rate | 8.04% | - | 20.12% | 19.70% | - |